We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The University of Oxford is ready to launch a phase 3 trial in Brazil of AstraZeneca (AZ)’s COVID-19 vaccine candidate, considered by the World Health Organization (WHO) to be the frontrunner in the research race. Read More
After weeks of waiting, Gilead Sciences announced yesterday that it will charge U.S. insurers $3,120 for a six-vial, five-day course of remdesivir, and a lower price of $2,340 for governments of developed countries, including the U.S. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with the Stevanato Group to help solve a serious problem facing vaccine manufacturers as they scale up production — a global shortage of glass vials. Read More
China has approved phase 1 trials of a COVID-19 vaccine candidate being developed by the country’s military in collaboration with two Chinese companies. Read More
The World Health Organization (WHO) has unveiled a plan to deliver 2 billion doses of COVID-19 vaccines to low- and middle-income countries by the end of 2021, but says it needs almost $28 billion to help fund the initiative, which also includes therapeutics and diagnostics. Read More
The vaccine candidate is stable at room temperature, which offers “an enormous logistical advantage in large vaccination campaigns,” the company said. Read More
As the race to develop an effective COVID-19 vaccine by year’s end gains momentum, the FDA said it plans to issue a guidance on developing and licensing them. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) yesterday recommended granting Gilead Sciences’ remdesivir a conditional marketing authorization as a COVID-19 treatment. Read More